AEG vs MET: Which Is the Better Buy in 2026?
Last updated November 2026
Short answer
MET is the larger of the two ($64.25B market cap): the incumbent the market prices for continued execution (9.16x forward earnings, beta 0.77). AEG is the smaller challenger ($12.59B), priced similarly on forward earnings (9.24x): more room to run, but more to prove. The real question is which set of drivers you believe, and whether owning one (or both) leaves you over-concentrated.
AEG vs MET: the tie-breaker metrics
Same yardstick, side by side (as of November 2026). Valuation lined up like this is most meaningful for two names in the same corner of the market, which these are. Figures are approximate; verify before investing.
| Metric | AEG | MET | What it tells you |
|---|---|---|---|
| Market cap | $12.59B | $64.25B | Size. The larger name is the incumbent; the smaller has more room to grow and more to prove. |
| Forward P/E | 9.24 | 9.16 | Valuation on next year's expected earnings, the same yardstick for both. Lower is cheaper for that growth; higher means the market is paying up. |
| Trailing P/E | 12.53 | 13.36 | Valuation on the last 12 months. A big drop from trailing to forward means the market expects earnings to jump, so more growth is already in the price. |
| Beta | 0.62 | 0.77 | Volatility vs the market. Above 1 swings harder than the index; below 1 is steadier. Higher beta means bigger drawdowns to hold through. |
| Price vs 52-week range | 66% of range | 89% of range | Where today's price sits between the 52-week low and high. Near the high is momentum with less margin of safety; near the low is out of favor or a discount, depending on why. |
| Price / book | 1.28 | 2.90 | How much you pay over book value. Very high can signal an asset-light, high-return business or a rich price. |
Before you buy: how AEG and MET affect your concentration
The metrics above tell you which is the marginally better business. The bigger risk for most people is not picking the slightly worse stock, it is over-concentrating. AEG and MET share themes, so owning both, or adding either to what you already hold, can quietly push a large share of your portfolio into one bet.
This is the part a generic comparison page cannot answer, because it depends on what you own. Connect your brokerage and Walnut shows your real, combined AEG and MET exposure, flags overlap with your existing positions, and tells you if adding one would tip you past a concentration you are comfortable with, read-only by default, with your login staying at your broker. Walnut is not an investment adviser.
What does Aegon Ltd. (AEG) do?
Aegon Ltd is a life insurance and retirement group whose center of gravity has shifted almost entirely to the United States. The dominant business is Transamerica, which sells individual life insurance, annuities, workplace retirement plans and mutual funds, and distributes much of that through World Financial Group, an agent network that passed 100,000 licensed agents in the first half of 2026. Outside the US, the group runs a UK workplace pensions and adviser platform, a joint venture with Santander across Spain and Portugal, an interest in Mongeral Aegon in Brazil, and an asset management arm. The company sold its Dutch insurance operations to a.s.r. in 2023 and has been steadily simplifying what remains. Roughly 12,100 people work there, and the reporting currency is still the euro even though the earnings are overwhelmingly dollar-denominated.
What does MetLife (MET) do?
MetLife, Inc. is one of the world's largest providers of life insurance, employee benefits, annuities, and asset management, serving individuals and institutional clients across the United States, Asia, Latin America, Europe, the Middle East, and Africa. It reports through several segments, including Group Benefits (group life, dental, disability, and other workplace coverage), Retirement and Income Solutions (annuities, pension risk transfers, structured settlements, and stable value products), Asia, Latin America, EMEA, and MetLife Holdings, its book of legacy US business. The core model is classic insurance: collect premiums, pay claims and benefits over time, and invest the difference (the float) in a large fixed-income-heavy portfolio, earning a spread. That makes MetLife both an underwriter and a giant investor, so its profitability depends on disciplined pricing, mortality and morbidity trends, and the returns it earns on invested assets.
AEG vs MET: how do they differ?
Both fit overlapping themes, but they are not interchangeable. The useful comparison is which set of drivers and risks you want exposure to.
- AEG drivers: Becoming an American company on paper, not just in practice; Capital generation drives a mechanical return of cash.
- MET drivers: Group Benefits and workplace demand; Retirement and Income Solutions.
Which fits which kind of investor
A faster-growing, richer-valued name usually swings harder, so it suits a longer horizon and a higher tolerance for volatility; a steadier, more cash-generative business suits a more conservative or income-minded investor. A useful test is which set of risks you could hold through a drawdown: The legacy American book is the reason the multiple is low: Transamerica carries long-term care and older universal life liabilities whose reserve adequacy depends on morbidity, mortality, lapse and claim-cost assumptions that get revisited annually, and an adverse review can wipe out a year of earnings growth in one press release. For MET, metLife's biggest risks come from the same levers that drive its profits.
AEG or MET: which should you pick?
Growth-minded investors who believe the theme has years to run tend to accept the richer multiple for more upside; value-minded investors lean toward the cheaper forward earnings and steadier profile. Pick AEG if you believe its drivers more; MET if you believe its. Many investors hold both, but since they share themes, that is a concentrated bet, not diversification. Decide deliberately and check overlap. For the full detail, see the AEG and MET guides.
AEG vs MET: the full fundamentals
AEG. Aegon reports in euros on a half-yearly calendar, so the trailing US-dollar figures above come from Yahoo Finance conversions and will not line up exactly with the company's own releases. The latest print was the first-half 2026 report on August 20, 2026, in which management said Transamerica's operating result rose about 10 percent and its operating capital generation about 35 percent; the next substantive results are the full-year 2026 figures, expected early in 2027. At roughly 9 times forward earnings and a yield near 6%, the shares still price in a discount that the October 2026 redomiciliation approval has not yet closed.
MET. At about $101.80 on October 16, 2026, MetLife trades near 9 times forward adjusted earnings, while the trailing GAAP P/E near 19.5x is inflated by investment and actuarial items that adjusted figures exclude. The 16 analysts tracked by Yahoo Finance hold a mean target near $107, and JPMorgan and Wells Fargo both lifted targets to $110 in mid-October. Insurer results swing with rates, credit markets and assumption updates, so reported and adjusted numbers can differ sharply.
Headline figures (approximate, October 2026): AEG shows share price / market cap ~$8.37 (Oct 16, 2026), ~$12.4 billion, share price change ~+8% YTD, ~+11% over 1 year, ~-8% over 3 months, revenue (ttm) ~$11.7 billion, latest reported period down ~8% year over year, net income (ttm) ~$970 million, EPS ~$0.69; profit margin ~8.6%; MET shows revenue (ttm) ~$79.4 billion, up ~10.5% YoY in Q2 2026, net income (ttm) ~$3.4 billion GAAP (~4.6% net margin), adjusted eps Q2 2026 $2.43 vs $2.29 estimate; 2026 consensus ~$10.21, p/e ~19.5x trailing GAAP, ~9x forward adjusted.
The bottom line: AEG vs MET
AEG and MET are related but distinct: same themes, different businesses and risks. Neither wins in the abstract; the right pick is whichever thesis you actually believe, sized so you are not over-concentrated in one theme. Walnut can show your combined AEG and MET exposure against your real portfolio. It is not an investment adviser.
Wondering how AEG or MET fits the portfolio you already own? Walnut is an AI investing app that connects your brokerage read-only and answers questions like that about your actual holdings: overlap, concentration, and how each position tracks the S&P 500. Compare the best AI portfolio analyzers or see the best AI investing apps in 2026.
Your questions about Aegon Ltd.
Ask Walnut's AI anything about AEG and see how it fits what you own.
FAQ
What is the difference between AEG and MET?
+
Aegon Ltd is a life insurance and retirement group whose center of gravity has shifted almost entirely to the United States. MetLife, Inc. They show up together because they share investment themes, but they are different businesses, so the better fit depends on which thesis you are expressing.
Is AEG or MET the better stock?
+
Neither is universally better. MET is the larger incumbent; AEG is the smaller challenger and looks pricier on forward earnings. Walnut is informational, not investment advice. Compare what each does, the tie-breaker metrics above, and the risks, then decide which fits your thesis and what you already own.
Which is cheaper, AEG or MET?
+
On forward P/E (as of November 2026), AEG trades at 9.24x and MET at 9.16x, so MET is the cheaper of the two on next year's expected earnings. A lower multiple is not automatically the better buy: a richer valuation can be justified by faster growth, and a lower one can reflect real risk. Weigh the multiple against how fast each business is compounding.
Should you own both AEG and MET?
+
Because they share themes, owning both concentrates you in that theme. That can be intentional (a focused bet) or accidental (less diversification than it looks). Walnut can show your combined exposure across both, and whether adding either over-concentrates you, before you buy.
What are the risks of AEG vs MET?
+
AEG: The legacy American book is the reason the multiple is low: Transamerica carries long-term care and older universal life liabilities whose reserve adequacy depends on morbidity, mortality, lapse and claim-cost assumptions that get revisited annually, and an adverse review can wipe out a year of earnings growth in one press release. Earnings and capital are sensitive to interest rates, credit spreads and equity markets at the same time, so a credit cycle that hits the fixed income portfolio while equity-linked fee income falls would pressure both sides. The shareholder vote has passed, but the redomiciliation is not finished: the legal move is not effective until around January 1, 2028, and it still involves regulatory steps, a transition of the group's capital framework from Bermuda and Solvency II toward US-style supervision, and a change from IFRS to US GAAP that will restate how earnings look. Any of those can slip or surprise. Reporting stays in euros until then while cash flows are mostly dollars, so translation adds noise that has nothing to do with underlying performance. Rate competition in annuities from well-capitalized private-credit-backed rivals can also compress spreads faster than the company's own repricing cycle. The stock has also given back ground lately, down about 8% over three months to October 16, 2026. MET: MetLife's biggest risks come from the same levers that drive its profits. As a large investor of policyholder float, it is exposed to interest-rate swings, credit spreads, and equity-market moves: sharp rate changes affect both investment income and the value of long-duration liabilities, and a credit downturn could pressure its bond and commercial-real-estate holdings. Insurance-specific risks include mortality, morbidity, and longevity assumptions proving wrong, plus reserve adequacy on long-tail liabilities like pensions and annuities. Its international earnings add currency and local-regulatory risk. Reported net income can be lumpy because of actuarial assumption updates, derivative marks, and market-related items, which is why the company emphasizes adjusted earnings. Insurance is also heavily regulated and capital-intensive, so statutory capital requirements and rating-agency views constrain how much can be returned to shareholders. After a 27% rise in 2026 the shares sit close to the analyst mean target of about $107 (October 2026), so less of the capital-return story is left unpriced than a year ago.
Walnut is informational, not investment advice. This page is descriptive and not a recommendation to buy or sell AEG or MET; figures are approximate and dated (as of November 2026). Verify current data before investing.